As a hub for Guangzhou’s biomedical industry, Huangpu District is home to more than 4,800 biomedical enterprises. Leveraging its comprehensive industrial chain, the district has significantly upgraded its research and development capabilities. In pharmaceutical and cosmetic testing, organoids and organ-on-a-chip technologies—which simulate human organs or provide alternatives to animal testing—are becoming increasingly widespread.

Researchers have developed organ chips for various human tissues, including the skin, cornea, intestine, joints, liver, gums, and neuro-immune interfaces. These chips are now widely used across four major fields—routine testing, food and cosmetics, medicine, and pharmaceuticals—providing effective solutions for multiple industries.

This emerging technology can accurately replicate human organs and disease conditions, enabling more precise drug screening while significantly reducing the trial-and-error costs of new drug development. Huangpu District has established a fully integrated biomedical industry ecosystem spanning upstream research and testing, drug screening, downstream clinical treatment, and commercial deployment. Homegrown advanced technologies are rapidly moving toward large-scale practical application, continuously strengthening the district’s core competitiveness in the biomedical sector.